Matt Hoffman

The SPI2 study did not replicate the improvements observed in prior study, instead suggesting that biotin (MD1003; MedDay Pharmaceuticals) is ineffective in patients with progressive MS.

Patients treated surgically reported better outcomes, including reduced AED use, higher rates of survival, and fewer epilepsy-related ED visits, hospitalizations, and outpatient visits.

Kristina Simonyan, MD, PhD, DrMed, and Davide Valeriani, PhD, discussed the translational potential of DystoniaNet, and its potential to be adjusted for use in additional disease states.

The Theranica Biotherapeutics remote electrical neuromodulation device is now cleared for the acute treatment of migraine with or without aura in adults, without limitation to episodic migraine.

The lead investigator of the study and assistant professor of neurology at University of Colorado School of Medicine, Jacob Pellinen, MD, spoke to the importance of identifying nonmotor seizures.

A number of poster presentations suggest that fenfluramine (Fintepla; Zogenix) offers a high percentage of patients with Dravet syndrome an opportunity to reduce monthly convulsive seizure frequency

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Raman Malhotra, MD.

Experts in the diagnosis and treatment of Duchenne muscular dystrophy share their perspectives on the complex care of this patient population in the NeurologyLive® Insights series “Management of Duchenne Muscular Dystrophy.”

The findings of this multicenter cohort may have implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB.

Kristina Simonyan, MD, PhD, DrMed, and Davide Valeriani, PhD, offered insight into the use of DystoniaNet, which identified the condition with 98.8% accuracy in a matter of 0.36 seconds.

For those with nonmotor seizures at onset who developed seizures with motor involvement later, the median number of days to diagnosis from motor symptom onset was only 13 days, compared to 616 days for the overall nonmotor group.

The combination agent resulted in a 44% lower risk of death for patients with ALS, with a 6.5-month longer median survival compared with placebo.

The recently approved oral solution, known as JZP-28 (Xywav), was associated with clinically meaningful improvements in Epworth Sleepiness Scale, Patient Global Impression of Change, and Idiopathic Hypersomnia Severity Scale scores.

If approved, rimegepant will be the first and only anti-CGRP agent indicated for both the preventive and acute treatment of migraine.

The multinational data revealed a risk of stroke of 0.5%, with the need for mechanical ventilation and the presence of ischemic heart disease being the most predictive indicators of stroke.

The investigators noted that their results can be replicated independently in a real-world cohort, they may have clinical implications for daily practice.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Costantino Iadecola, MD.

Data from a long-term phase 2 study in episodic migraine suggest that those treated with erenumab maintain reductions in both monthly migraine days and use of acute migraine medications in the long-term.

Patients treated with Axovant’s gene therapy AXO-Lenti-PD reported improvements of 40% in UPDRS-III scores, and 71% improvement in activities of daily living.

Results from a 24-week phase 2a trial and its 2-year extension suggest that patients taking vamorolone experienced motor outcome improvements compared to corticosteroid-naïve individuals.

The initiative, funded by Jazz, will include educational multimedia content such as a series of podcasts with expert interviews discussing sleep and related disorders.

Julio J. Fernandez-Mendoza, PhD, a clinician-scientist at Penn State Hershey Sleep Research & Treatment Center, of Penn State Health, spoke to the implications of a recent study he and colleagues conducted.

Solid Biosciences noted that its response to the agency requests for further information about manufacturing as well as updated safety and efficacy data on all dosed patients led to the lift.

Zosano Pharma noted that the DRL does not reflect the final FDA decision on the application, though the approval of zolmitriptan by its PDUFA action date of October 20, 2020, is no longer likely as a result.

The investigators noted that continuous non-invasive blood pressure monitoring upon standing may aid in the identification of a modifiable risk factor for syncope-related falls in patients with Parkinson disease.

Post hoc analysis of the ATACH-II trial suggest that intensive lowering of systolic blood pressure in individuals with initial levels ≥220 mmHg increases the rate of neurological deterioration over 24 hours.

The medical director manager of neuroscience at Genentech offered her perspective on the mountain of data presented at MS Virtual 2020 on the recently approved NMOSD treatment.

Aquestive Therapeutics plans to provide the agency with information on pharmacokinetic modeling to demonstrate that the desired levels of diazepam exposure can be achieved with dose adjustments.

The platform, dubbed DystoniaNet, was able to identify 3 varieties of focal dystonia in a matter of 0.36 seconds with almost 100% accuracy.

The findings suggest that this insomnia phenotype is a more biologically severe form of the disorder associated with cardiovascular, cerebrovascular, and neurocognitive morbidity.